Helal M. Ahmed

Ratzeburger Allee 160
Luebeck, SH 23538, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort.

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort.

Journal: Leukemia & lymphoma

Published: July 28, 2026

Precision Oncology in Northern Germany - Integrating Multi-Omics and AI to Support Evidence-Based Molecular Tumor Boards.

Precision Oncology in Northern Germany - Integrating Multi-Omics and AI to Support Evidence-Based Molecular Tumor Boards.

Journal: Oncology research and treatment

Published: February 04, 2026

FASTINA - protocol for a randomised feasibility trial of time-restricted eating to improve response to multiple myeloma therapy.

FASTINA - protocol for a randomised feasibility trial of time-restricted eating to improve response to multiple myeloma therapy.

Journal: Pilot and feasibility studies

Published: February 02, 2026

Impact of Acute Myeloid Leukemia Cells on the Metabolic Function of Bone Marrow Mesenchymal Stem Cells.

Impact of Acute Myeloid Leukemia Cells on the Metabolic Function of Bone Marrow Mesenchymal Stem Cells.

Journal: International journal of molecular sciences

Published: April 11, 2025

Germline Single-Nucleotide Polymorphism GFI1-36N Causes Alterations in Mitochondrial Metabolism and Leads to Increased ROS-Mediated DNA Damage in a Murine Model of Human Acute Myeloid Leukemia.

Germline Single-Nucleotide Polymorphism GFI1-36N Causes Alterations in Mitochondrial Metabolism and Leads to Increased ROS-Mediated DNA Damage in a Murine Model of Human Acute Myeloid Leukemia.

Journal: Biomedicines

Published: November 13, 2024

Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot Study.

Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot Study.

Journal: International journal of molecular sciences

Published: October 31, 2024

Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cells.

Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cells.

Journal: British journal of haematology

Published: August 30, 2022

Presence of the GFI1-36N single nucleotide polymorphism enhances the response of MLL-AF9 leukemic cells to CDK4/6 inhibition.

Presence of the GFI1-36N single nucleotide polymorphism enhances the response of MLL-AF9 leukemic cells to CDK4/6 inhibition.

Journal: Frontiers in oncology

Published: March 24, 2022

Inhibiting PI3K-AKT-mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells.

Inhibiting PI3K-AKT-mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells.

Journal: Frontiers in oncology

Published: February 12, 2022

Dose-dependent effect of GFI1 expression in the reconstitution and the differentiation capacity of HSCs.

Dose-dependent effect of GFI1 expression in the reconstitution and the differentiation capacity of HSCs.

Journal: Frontiers in cell and developmental biology

Published: January 31, 2022

Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells.

Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells.

Journal: British journal of haematology

Published: June 16, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026